TNGX:NASDAQTango Therapeutics, Inc. Analysis
Data as of 2026-08-01 - not real-time
$27.18
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Tango Therapeutics (TNGX) is trading at $27.18, comfortably above its 20‑day SMA of 28.47 and 50‑day SMA of 27.39, indicating a short‑term bullish bias, while the 200‑day SMA sits near 17.46, underscoring a longer‑term uptrend. Momentum metrics are mixed: RSI is at 46.9 (neutral) and MACD shows a bearish histogram, and volume has been decreasing, suggesting caution ahead of the next catalyst. The stock carries a premium valuation with a price‑to‑book of 10.0× and a price‑to‑sales of 77.6×**, alongside a negative PE and operating losses, but it is bolstered by a strong cash position of $379 M versus $33 M of debt.
Recent material news includes the appointment of seasoned biotech executive Robert Azelby to the board and analyst upgrades that lifted the target price to $46, implying over 60% upside. These developments, combined with the pending late‑stage data for the PRMT5 inhibitor vopimetostat, drive the medium‑term upside narrative, while the high 30‑day volatility (≈76%) and beta (≈1.3) keep short‑term risk elevated.
Recent material news includes the appointment of seasoned biotech executive Robert Azelby to the board and analyst upgrades that lifted the target price to $46, implying over 60% upside. These developments, combined with the pending late‑stage data for the PRMT5 inhibitor vopimetostat, drive the medium‑term upside narrative, while the high 30‑day volatility (≈76%) and beta (≈1.3) keep short‑term risk elevated.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Mixed technical signals (bullish SMA alignment vs bearish MACD)
- Decreasing volume and high short‑term volatility
- Pending data releases could cause price swing
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Analyst target raise to $46 and 63% upside potential
- Board appointment adds commercialization expertise
- Potential late‑stage trial data for vopimetostat
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Strategic focus on precision oncology with multiple pipeline candidates
- Strong cash runway relative to modest debt
- Long‑term growth narrative despite current earnings losses
Key Metrics & Analysis
Financial Health
Profit Margin-188.15%
P/E Ratio-17.9
ROE-38.42%
ROA-20.69%
Debt/Equity8.38
P/B Ratio10.0
Op. Cash Flow$-141548992
Free Cash Flow$-68235000
Industry P/E29.2
Technical Analysis
TrendBullish
RSI47.0
Support$25.33
Resistance$32.17
MA 20$28.47
MA 50$27.39
MA 200$17.46
MACDBearish
VolumeDecreasing
Fear & Greed Index92.88
Valuation
Target Price$44.33
Upside/Downside63.11%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta1.32
Volatility76.26%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.